The neuroendocrinology of the preoptic area in menopause: Symptoms and therapeutic strategies

Modi, Manish; Dhillo, Waljit

doi:10.1016/b978-0-12-819975-6.00029-7

Cited by 5 publications

(6 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…[49][50][51][52][53][54] Moreover, we also studied NT-814, which is an NK1R and NK3R dual antagonist. [49] It is proposed that the lowering of estrogen levels among women undergoing menopause is the key cause of VMS. [55][56][57][58] However, the exact origin of the mechanism behind the altering estrogen levels is currently unclear.…”

Section: Discussionmentioning

confidence: 99%

“…The recent years have also been a testament to NK3R antagonism pathways that can serve as a viable alternative to the current gold standard of hormone replacement therapy among menopausal women. [49,[75][76][77] www.md-journal.com NK3 receptor antagonists-MLE4901 were first tested in a randomized, double-blind, placebo-controlled trial in 2017 among women aged 40 to 62. [31] Prague et al [31] randomized controlled trial, MLE4901 led to a reduction of 45% in hot flush frequency.…”

Section: Discussionmentioning

confidence: 99%

“…[78] NK1R site occupancy has also been extrapolated based on in vitro affinity ratios. [49,50,79] The postulation of NT-814 dosage required to occupy 95% of all NK1 receptors is for an occupation of nearly 67% of all NK3 receptors; this can antagonize NKB and NK3R central signaling. [62,80] The data provides insights into the potential hypothalamic effects of peripheral administration of NK3R antagonists to counteract heat dissipation responses seen among women experiencing hot flushes.…”

Section: Discussionmentioning

confidence: 99%

“…We reviewed pharmacologic agents including fezolinetant (ESN364) and pavinetant (MLE4901); both are antagonists of NK3R. [49][50][51][52][53][54] Moreover, we also studied NT-814, which is an NK1R and NK3R dual antagonist. [49] It is proposed that the lowering of estrogen levels among women undergoing menopause is the key cause of VMS.…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Neurokinin 1/3 receptor antagonists for menopausal women: A current systematic review and insights into the investigational non-hormonal therapy

Hassan¹,

Saleem²,

Samuel³

et al. 2023

Medicine

View full text Add to dashboard Cite

Background: Over 75% of menopausal women experience vasomotor symptoms (VMS), such as night sweats and hot flashes. Despite the prevalence of these symptoms, there is limited data on non-hormonal therapies to alleviate them. Methods: PubMed, Cochrane, Scopus, Ovid, Web of Science, and ClinicalTrials.Gov were searched for relevant studies. The search was performed using the following keywords, which were customized to suit the specific databases/registers: menopause, women, neurokinin 3, and/or Fezolinetant. The search was conducted until December 20, 2022. This systematic review was conducted in compliance with the PRISMA Statement 2020 guidelines. Results: A total of 326 records were found, with 10 studies (enrolling 1993 women) selected for inclusion. The women received 40-mg doses of NK1/3 receptor antagonists twice daily, with follow-ups at 1 to 3 weeks. Moderately strong evidence was found suggesting that NK1/3 receptor antagonists can help limit the frequency and severity of hot flashes in menopausal women. Conclusion: While the results should be interpreted with caution until further clinical trials validate the efficacy and safety of NK1/3 receptor antagonists among menopausal women, these findings suggest that they are promising targets for future pharmacological and clinical studies in addressing vasomotor symptoms.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Neurokinin 1/3 receptor antagonists for menopausal women: A current systematic review and insights into the investigational non-hormonal therapy

Hassan¹,

Saleem²,

Samuel³

et al. 2023

Medicine

View full text Add to dashboard Cite

show abstract

Endocrine effects of heat exposure and relevance to climate change

Hannan,

Leow,

Lee

et al. 2024

Nat Rev Endocrinol

View full text Add to dashboard Cite

Management of perimenopausal and menopausal symptoms

Duralde

Sobel

Manson

2023

BMJ

View full text Add to dashboard Cite

Most women worldwide experience menopausal symptoms during the menopause transition or postmenopause. Vasomotor symptoms are most pronounced during the first four to seven years but can persist for more than a decade, and genitourinary symptoms tend to be progressive. Although the hallmark symptoms are hot flashes, night sweats, disrupted sleep, and genitourinary discomfort, other common symptoms and conditions are mood fluctuations, cognitive changes, low sexual desire, bone loss, increase in abdominal fat, and adverse changes in metabolic health. These symptoms and signs can occur in any combination or sequence, and the link to menopause may even be elusive. Estrogen based hormonal therapies are the most effective treatments for many of the symptoms and, in the absence of contraindications to treatment, have a generally favorable benefit:risk ratio for women below age 60 and within 10 years of the onset of menopause. Non-hormonal treatment options are also available. Although a symptom driven treatment approach with individualized decision making can improve health and quality of life for midlife women, menopausal symptoms remain substantially undertreated by healthcare providers.

show abstract

The neuroendocrinology of the preoptic area in menopause: Symptoms and therapeutic strategies

Cited by 5 publications

References 41 publications

Neurokinin 1/3 receptor antagonists for menopausal women: A current systematic review and insights into the investigational non-hormonal therapy

Neurokinin 1/3 receptor antagonists for menopausal women: A current systematic review and insights into the investigational non-hormonal therapy

Endocrine effects of heat exposure and relevance to climate change

Management of perimenopausal and menopausal symptoms

Contact Info

Product

Resources

About